CS Pharmaceuticals (CSP) has acquired AxeroVision for an undisclosed fee, in a move that will involve a dry eye disease (DED) candidate being transferred over to the UK-based ocular therapeutics company.
CSP, which is headquartered in London but develops and commercialises treatments for eye diseases in China, will continue developing AXR-270, a selective glucocorticoid receptor agonist. The drug has been in a phase of developmental dormancy. In August 2021, AxeroVision released positive Phase II results for the candidate in 129 patients with DED with meibomian gland dysfunction (MGD).
Go deeper with GlobalData
In a statement announcing the 2021 results, AxeroVision – which spun out from GSK in 2016 – said it was planning to enrol around 800 patients in a Phase III trial comparing the eye cream with a vehicle, and a new drug application/marketed authorisation application filing expected in 2024. However, the company did not issue any further updates on the drug since then.
AXR-270, which CSP now has exclusive rights to use in ophthalmology, is applied as a cream once daily to the eyelid. The cream formulation helps overcome limitations with eyedrops. Eyedrops need to be dosed four times a day and the drug can be lost from the application area due to tearing. AXR-270 is absorbed into the meibomian gland and is delivered to the eye surface each time the patient blinks.
The incidence, or the number of new cases in a given population, of DED in Asia is approximately 17%. A sales forecast by GlobalData estimates that the 2028 dry eye disease drug market in the Asia-Pacific region will be worth $9.3bn.
Darren Mercer, chief executive at CSP said: “On the basis of the very unique product features and strong phase II clinical data, we strongly believe that AXR-270 will provide huge clinical benefits to patients. Having secured the global rights, we will now seek a partner for ex-China rights to collaborate with, in the development of AXR-270 for the USA, Europe and other markets.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
